Protalix BioTherapeutics, Inc. (AMEX: PLX), announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE